QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-115

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price targ...

 biomarin-presents-data-highlighting-impact-of-voxzogo-in-bone-health-and-health-related-quality-of-life-in-achondroplasia-at-2024-iccbh

New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of...

 biomarin-presents-new-phase-3-4-year-data-underscoring-long-term-safety-and-efficacy-of-roctavian-at-international-society-on-thrombosis-and-haemostasis-2024-congress-in-bangkok-thailand-june-22-26-2024

Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression...

 li-auto-was-one-of-the-worst-performing-stocks-last-week-are-these-10-large-cap-stocks-losers-in-your-portfolio-may-12-may-18-2024

Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw sign...

 baird-downgrades-biomarin-pharmaceutical-to-neutral-lowers-price-target-to-72

Baird analyst Joel Beatty downgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Neutral and lowers the price t...

 biomarin-pharmaceutical-to-cut-about-170-employees

-SEC Filing

 evercore-isi-group-initiates-coverage-on-biomarin-pharmaceutical-with-outperform-rating-announces-price-target-of-113

Evercore ISI Group analyst Cory Kasimov initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating...

 reported-saturday-biomarin-presented-new-data-on-voxzogo-for-multiple-growth-related-conditions-in-children-presented-at-pediatric-endocrine-society-pes-annual-meeting

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature...

 morgan-stanley-maintains-overweight-on-biomarin-pharmaceutical-lowers-price-target-to-112

Morgan Stanley analyst Matthew Harrison maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the pri...

 canaccord-genuity-maintains-hold-on-biomarin-pharmaceutical-lowers-price-target-to-89

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price targ...

 citigroup-maintains-neutral-on-biomarin-pharmaceutical-lowers-price-target-to-91

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target ...